| Diabetic Neuropathy |
0 |
0.95 |
| Peripheral Neuropathy |
0 |
1 |
| Diabetic Peripheral Neuropathy |
0 |
0.77 |
| Neuropathy |
0 |
0.85 |
| Pain Management |
0 |
0.54 |
| Motor Neuropathy |
0 |
0.53 |
| Sensory Neuropathy |
0 |
0.53 |
| Autonomic Neuropathy |
0 |
0.52 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
0 |
0.33 |
| HIV Infection |
0 |
0.33 |
| Biologic Therapy |
0 |
0.24 |
| Nerve |
0 |
0.24 |
| Neuropathic Pain |
0 |
0.22 |
| Neuron |
0 |
0.2 |
| Pain |
0 |
0.2 |
| Toxicology |
0 |
0.17 |
| Healthcare and Medical Technology |
0 |
0.16 |
| Patient Safety |
0 |
0.14 |
| Depression |
0 |
0.11 |
| Head and Neck Cancer |
0 |
0.1 |
| Clinical Research |
0 |
0.09 |
| Colorectal Cancer |
0 |
0.09 |
| Genomic Medicine |
0 |
0.08 |
| Antineoplastic Drug |
0 |
0.07 |
| Cancer |
0 |
0.07 |
| Chemotherapy |
0 |
0.07 |
| Hepatitis B Virus |
0 |
0.07 |
| Pedal |
0 |
0.07 |
| Type 2 Diabetes Mellitus |
0 |
0.07 |
| Vitamin |
0 |
0.07 |
| Brain Cancer |
0 |
0.06 |
| Demyelination |
0 |
0.06 |
| Gastrointestinal Cancer |
0 |
0.06 |
| Immunoglobulin G (IgG) |
0 |
0.06 |
| Monoclonal Antibody |
0 |
0.06 |
| Acute Leukemia |
0 |
0.05 |
| Avitaminosis A |
0 |
0.05 |
| Cerebrospinal Fluid |
0 |
0.05 |
| Chronic Lymphocytic Leukemia |
0 |
0.05 |
| Epilepsy |
0 |
0.05 |
| Opioids |
0 |
0.05 |
| Plantar |
0 |
0.05 |
| Receptors |
0 |
0.05 |
| Dorsum |
0 |
0.04 |
| Exercise |
0 |
0.04 |
| Platinum |
0 |
0.04 |
| Acute Lymphoblastic Leukemia |
0 |
0.03 |
| Addiction |
0 |
0.03 |
| Analgesia |
0 |
0.03 |
| Antidepressant drug |
0 |
0.03 |
| Autoimmune Disease |
0 |
0.03 |
| Biomarker |
0 |
0.03 |
| Brain |
0 |
0.03 |
| Complementary and Alternative Medicine |
0 |
0.03 |
| Cyclic Antidepressants |
0 |
0.03 |
| Intravenous Immunoglobulin (IVIG) |
0 |
0.03 |
| Leukemia |
0 |
0.03 |
| Meta-Analysis |
0 |
0.03 |
| Plasmapheresis |
0 |
0.03 |
| Quality of Life |
0 |
0.03 |
| Refractory |
0 |
0.03 |
| Translational Research |
0 |
0.03 |
| Adverse Effects |
0 |
0.02 |
| Anticonvulsant |
0 |
0.02 |
| Clinical Guidelines |
0 |
0.02 |
| Diabetes Mellitus |
0 |
0.02 |
| Ganglion |
0 |
0.02 |
| Immunoglobulin A (IgA) |
0 |
0.02 |
| Microbiome |
0 |
0.02 |
| mTOR Inhibitor |
0 |
0.02 |
| Muscular Atrophy |
0 |
0.02 |
| Obesity |
0 |
0.02 |
| Osteoarthritis |
0 |
0.02 |
| Paresthesia |
0 |
0.02 |
| Plasma |
0 |
0.02 |
| Point-of-Care |
0 |
0.02 |
| Skin and Soft Tissue Infection |
0 |
0.02 |
| SNRI |
0 |
0.02 |
| Tropical Diseases |
0 |
0.02 |
| Ultrasonography |
0 |
0.02 |
| Wound Management |
0 |
0.02 |
| Acupuncture |
0 |
0.01 |
| Allodynia |
0 |
0.01 |
| Amputation |
0 |
0.01 |
| Antioxidant |
0 |
0.01 |
| Atrial Fibrillation |
0 |
0.01 |
| Bladder |
0 |
0.01 |
| Blood |
0 |
0.01 |
| Burns |
0 |
0.01 |
| Calcium |
0 |
0.01 |
| Cellular Mechanism |
0 |
0.01 |
| Cervical Region |
0 |
0.01 |
| Child |
0 |
0.01 |
| Corticosteroids |
0 |
0.01 |
| CT Scan |
0 |
0.01 |
| Cytokines |
0 |
0.01 |
| Diphtheria |
0 |
0.01 |
| Disability |
0 |
0.01 |
| Drug Development |
0 |
0.01 |
| Europe |
0 |
0.01 |
| Food and Drug Administration (FDA) |
0 |
0.01 |
| Gland |
0 |
0.01 |
| Hand |
0 |
0.01 |
| Herpes Zoster |
0 |
0.01 |
| Immunodeficiency |
0 |
0.01 |
| Immunology |
0 |
0.01 |
| Immunosuppressive Therapy |
0 |
0.01 |
| Immunotherapy |
0 |
0.01 |
| Interleukin |
0 |
0.01 |
| Internet |
0 |
0.01 |
| Intravenous |
0 |
0.01 |
| Leprosy |
0 |
0.01 |
| Limb |
0 |
0.01 |
| Lung |
0 |
0.01 |
| Lyme Disease |
0 |
0.01 |
| Michigan |
0 |
0.01 |
| MicroRNA |
0 |
0.01 |
| Muscle |
0 |
0.01 |
| Myelin |
0 |
0.01 |
| Neurodegenerative Diseases |
0 |
0.01 |
| Neuroinflammation |
0 |
0.01 |
| Neuropharmacology |
0 |
0.01 |
| Neurotoxicity |
0 |
0.01 |
| Neutropenia |
0 |
0.01 |
| Nitric Oxide |
0 |
0.01 |
| Ophthalmic |
0 |
0.01 |
| Oxidative Stress |
0 |
0.01 |
| Pathogenesis |
0 |
0.01 |
| Pharmacodynamics |
0 |
0.01 |
| Pharmacokinetics |
0 |
0.01 |
| Prognosis |
0 |
0.01 |
| Prophylaxis |
0 |
0.01 |
| Proteasome Inhibitor |
0 |
0.01 |
| Rabies |
0 |
0.01 |
| Stress |
0 |
0.01 |
| Tdap Vaccine |
0 |
0.01 |
| Tissue |
0 |
0.01 |
| Traditional Chinese Medicine |
0 |
0.01 |
| Travel Medicine |
0 |
0.01 |
| Tumor |
0 |
0.01 |
| Vinca Alkaloid |
0 |
0.01 |
| Weakness |
0 |
0.01 |